Every material Form 8-K Protalix BioTherapeutics, Inc. has filed with the SEC since May 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Protalix reported second-quarter 2026 total revenue of $19.9 million, up from $15.7 million a year earlier, and net income of $3.8 million, or $0.05 per share, compared with $164,000 in the same quarter of 2025. The company reaffirmed its full-year 2026 total revenue outlook of $78.0 million to $83.0 million, which includes a $25.0 million Chiesi milestone already received, and reported $40.7 million in cash and short-term deposits at June 30, 2026.
Q2 2026 total revenue was $19.9 million versus $15.7 million in Q2 2025; sales of goods rose $4.4 million to $19.8 million, driven mainly by sales to Chiesi and Fiocruz (Brazil).
Net income for the six months ended June 30, 2026 was $22.1 million, or $0.27 per diluted share, compared with a net loss of $3.5 million a year earlier; the period includes the $25.0 million Chiesi milestone.
2026 guidance reiterated: total revenue of $78.0 million to $83.0 million, with Elfabrio sales excluding milestones of $33.0 million to $35.0 million and Elelyso sales of $20.0 million to $23.0 million.
Top-line results from the PRX-115 Phase 2 RELEASE trial are anticipated in the second half of 2027.
Protalix BioTherapeutics furnished a May 2026 corporate presentation on its website as Exhibit 99.1 to an 8-K filed May 21, 2026. The deck reiterates Q1 2026 revenue of $33.8 million, including a $25 million Chiesi milestone, and $51.1 million in cash as of March 31, 2026 with no debt. The filing itself contains no new financial results or guidance.
Q1 2026 revenue of $33.8 million, including a $25 million regulatory milestone from Chiesi
Cash of $51.1 million as of March 31, 2026; no debt or warrants
Approximately 80.5 million shares of common stock outstanding as of May 1, 2026
PRX-115 Phase 2 RELEASE trial in uncontrolled gout is enrolling, with top-line results anticipated in 2H 2027
Protalix reported first-quarter 2026 total revenue of $33.8 million, up from $10.1 million a year earlier, and net income of $18.3 million, compared with a net loss of $3.6 million in the prior-year quarter. The increase was driven mainly by a $25.0 million milestone from partner Chiesi, and the company reaffirmed its 2026 total revenue guidance of $78.0 million to $83.0 million, which includes that milestone.
Total revenue was $33.8 million for the quarter ended March 31, 2026, versus $10.1 million a year earlier.
Net income was $18.3 million, or $0.23 per share basic and $0.22 diluted, versus a net loss of $3.6 million, or $(0.05) per share, in Q1 2025.
Revenue from selling goods fell to $7.4 million from $10.0 million, mainly due to a timing shift in Pfizer's Elelyso purchases.
The company reaffirmed 2026 total revenue guidance of $78.0 million to $83.0 million and reported cash and short-term deposits of $51.1 million as of March 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Protalix BioTherapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →